56. Behcet disease Clinical trials / Disease details
Clinical trials : 81 / Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00720928 (ClinicalTrials.gov) | July 2008 | 18/7/2008 | Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease | A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease | Ocular Behcet's Disease,;Non-Infectious Uveitis;Refractory Uveitis | Drug: flucinolone acetonide | Asan Medical Center | Samsung Medical Center;Seoul National University Hospital;Kyunghee University Medical Center | Recruiting | 18 Years | N/A | Both | 15 | Phase 4 | Korea, Republic of |